Hexarelin

≥98% HPLCCOA per batchCold-chain shippedIn-house synthesisResearch use only · not for human consumption

Price range: $43.99 through $62.99

Independently verified Tested by IRZC Laboratories Batch NHV26-J2347 · Purity 99.07 % HPLC · Issued 4 Aug 2026 · Cert COA-8SF9-TG4Q-YVerify at IRZCVerifyScan to verify

One of the most potent synthetic GH secretagogues, stimulating powerful GH release along with cardioprotective effects.

FormulaC47H58N12O6
Mol. weight887.04 g/mol
FormLyophilised powder
1 People watching this product now!
SKU: PEP-010 Category:

Molecular & analytical data

Verified chemistry and third-party reference identifiers for this compound.

Amino acid sequenceHis-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2
Molecular formulaC47H58N12O6
Molecular weight887.04 g/mol
CAS number140703-51-1
PubChem CIDCID 6918297 ↗
Purity standard≥98%
Half-life~70 minutes
BioavailabilitySubcutaneous: ~77%; Intranasal: ~4.8%; Oral: ~0.3% (biological bioavailability, Ghigo et al. 1994)
Origin / sourceSynthetic hexapeptide
Year discovered1990s
Hexarelin molecular structure
2D structure · source: PubChem

Reconstitution calculator

Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →

Concentration— mg/mL— mcg per unit
—Draw tounits on a U-100 syringe
—Volume / drawmL
—Complete drawsper vial

—

A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.

Quality & verification

Every batch is characterised before release and ships with documentation.

≥98%HPLC purity
887.04 g/molMolecular weight
~70 minutesReported half-life
MS + HPLCIdentity & purity assay
Third-party testedBatches are tested by IRZC Laboratories — independent HPLC + mass-spec confirms identity and purity against that product’s release specification.
Batch-matched COAA certificate of analysis is issued per batch and matched to your vial’s lot number.
Cold-chain fulfilmentLyophilised product is packed with insulated, temperature-controlled shipping.
Controlled synthesisProduced under documented, reproducible in-house processes with lot traceability.

Storage & handling

Keep the peptide stable from delivery through reconstitution.

1
On arrivalStore the sealed, lyophilised vial frozen at −20°C, protected from light and moisture.
2
ReconstitutionAdd bacteriostatic water down the vial wall; swirl gently — do not shake. Use the calculator above to plan volume.
3
After mixingRefrigerate the reconstituted solution at 2–8°C and use within the stability window below.
4
HandlingWork in a clean area, wipe the stopper with alcohol, and avoid repeated freeze–thaw cycles.
Manufacturer storage note

Lyophilized at -20°C. Reconstituted at 2-8°C.

Description

Hexarelin (also known as Examorelin) is one of the strongest synthetic growth hormone releasing peptides available. It produces more robust GH pulses than GHRP-2 or GHRP-6 but also has more pronounced side effects including significant cortisol and prolactin elevation. Uniquely, Hexarelin has demonstrated cardioprotective properties independent of GH release, through direct action on cardiac tissue. However, it is subject to desensitization with prolonged use, making cycling necessary.

Certificates of Analysis

Certificates of Analysis

Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.

Batch #IssuedPurityCertificate
NHV26-J2347
COA-8SF9-TG4Q-Y
04 Aug 202699.07 % HPLCVerify at IRZC ↗

“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.

Research & Literature
Reported in research literature — not usage guidance.

The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.

Mechanism of action

Potent ghrelin receptor agonist, strongest GH pulse of GHRPs, cardioprotective effects via CD36 receptor, increases cortisol and prolactin, subject to tachyphylaxis with chronic use.

Primary uses / indications

Maximum GH stimulation research, cardioprotection studies, muscle growth, body composition

Typical dosage (reported)

100-200 mcg per injection, 2-3 times daily. Cycle to prevent desensitization.

Cycle duration (reported)

4-8 weeks maximum due to desensitization; requires cycling

Administration route

Subcutaneous injection, Intravenous (research)

Side effects (reported)

Significant cortisol and prolactin elevation, intense hunger, water retention, desensitization with prolonged use, injection site reactions.

Contraindications

Active cancer, pituitary disorders, hyperprolactinemia, cardiac conditions, pregnancy/breastfeeding

Drug interactions

Synergistic with GHRH analogs. Subject to desensitization — cycling required.

Reviews (0)
0 reviews
0
0
0
0
0

There are no reviews yet.

Be the first to review “Hexarelin”

Your email address will not be published. Required fields are marked *

You have to be logged in to be able to add photos to your review.

Specifications

Identity

Full name / brand namesHexarelin (Examorelin)
CategoryGrowth Hormone Secretagogues
SubcategoryGhrelin Receptor Agonist (GHS)
Origin / sourceSynthetic hexapeptide
Year discovered1990s

Chemistry

Amino acid sequenceHis-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2
Molecular formulaC47H58N12O6
Molecular weight887.04 g/mol
CAS number140703-51-1
PubChem CIDCID 6918297 ↗
Purity standard≥98%

Pharmacokinetics

Half-life~70 minutes
BioavailabilitySubcutaneous: ~77%; Intranasal: ~4.8%; Oral: ~0.3% (biological bioavailability, Ghigo et al. 1994)

Regulatory & research status

FDA statusNot FDA-approved. Research chemical only.
Prescription requiredResearch use only
Research statusClinical studies for GH deficiency and cardioprotection; not approved
Clinical trialsPhase II trials (GH deficiency, cardiac function)

References

Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, "Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man", Journal of Clinical Endocrinology & Metabolism, 1994;78(3):693-698, DOI: 10.1210/jcem.78.3.8126144; Arvat E et al., "Effects of short-term continuous infusion of human GHRH and hexarelin on GH release", Journal of Endocrinological Investigation, 1994

Frequently asked questions

What is Hexarelin?
One of the most potent synthetic GH secretagogues, stimulating powerful GH release along with cardioprotective effects.
How does Hexarelin work?
Reported in the research literature: Potent ghrelin receptor agonist, strongest GH pulse of GHRPs, cardioprotective effects via CD36 receptor, increases cortisol and prolactin, subject to tachyphylaxis with chronic use.
What Hexarelin dosage is used in research?
For laboratory research reference only, not usage guidance: 100-200 mcg per injection, 2-3 times daily. Cycle to prevent desensitization.
What is the half-life of Hexarelin?
The reported biological half-life of Hexarelin is approximately ~70 minutes.
How should Hexarelin be stored and reconstituted?
NHOV ships Hexarelin as a lyophilised powder. Store unopened vials at −20 °C. Reconstitute with bacteriostatic water; once reconstituted, refrigerate at 2–8 °C, protect from light, and use within the bacteriostatic-water shelf window. Use the NHOV reconstitution calculator to find the exact volume for your target concentration.
What purity is NHOV's Hexarelin?
NHOV Hexarelin is released against a specification of ≥98%, verified by HPLC with mass-spectrometry identity confirmation, and ships with a batch-specific Certificate of Analysis (COA) matched to the vial's lot number.
Is Hexarelin approved for human use?
No. Hexarelin is sold strictly for laboratory and scientific research use only. It is not for human or veterinary consumption and is not approved as a drug.